Prospects of metformin in the treatment of endometriosis

Cover Page


According to recent year studies, the classical biguanide metformin has antiproliferative, proapoptotic and anti-inflammatory effects in addition to the main hypoglycemic effect. There are clinical and experimental studies these effects in the therapy of oncological and benign hyperplastic diseases. There is no data about the clinical efficacy of metformin in the therapy of endometriosis in the domestic literature, and there were a few studies in foreign sources. There was a decrease in the severity of the pain syndrome and an increase of pregnancy rate in two clinical studies with small samples. However, future studies are needed to investigate the mechanisms of the target drug effect and to develop effective regimens for the treatment of endometriosis.

Margarita S Florova

FSBSI “The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott”

Author for correspondence.

Russian Federation, Saint Petersburg, Russia

postgraduate student

Mariya I Yarmolinskaya

FSBSI “The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott”


Russian Federation, Saint Petersburg, Russia

professor of Russian Academy of Sciences, leading research assistant of department of endocrinology of reproduction, Doctor of medical sciences, head of center “Diagnostics and treatment of endometriosis”

Vladimir V Potin

FSBSI “The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott”


Russian Federation, Saint Petersburg, Russia

MD, PhD, Honoured figure, professor, Head of Department of Endocrinology

  1. Клинический протокол МЗ РК — 2013 «Эндометриоз». Утвержден Протоколом заседания Экспертной комиссии по вопросам развития здравоохранения МЗ РК № 23 от 12 декабря 2013 года. [Klinicheskij protokol MZ RK – 2013 “Jendometrioz”. Utverzhden Protokolom zasedanija Jekspertnoj komissii po voprosam razvitija zdravoohranenija MZ RK No 23, 12 December 2013. (In Russ.)] Доступно по: %8D%D0 %BD%D0 %B4 %D0 %BE%D0 %BC%D0 %B5 %D1 %82 %D1 %80 %D0 %B8 %D0 %BE%D0 %B7/13827. Ссылка активна на 09.03.2017
  2. Bulletti C, Coccia M, Battistoni S, et al. Endometriosis and infertility. Journal of Assisted Reproduction and Genetics. 2010;27(8):441-7. doi: 10.1007/s10815-010-9436-1.
  3. Diedrich K, Holzgreve W, Schultze-Mosgau A, et al. Gynäkologie Geburtshilfe. 2. Aufl. Heidelberg; 2007.
  4. Prescott J, Farland L, Tobias D, et al. A prospective cohort study of endometriosis and subsequent risk of infertility. Human Reproduction. 2016;31(7):1475-82. doi: 10.1093/humrep/dew085.
  5. Fedele L, Bianchi S, Zanconato G, et al. Laparoscopic excision of recurrent endometriomas: long-term outcome and comparison with primary surgery. Fertil Steril. 2006;85(3):694-9. doi: 10.1016/j.fertnstert.2005.08.028.
  6. Vignali M, Bianchi S, Candiani M, et al. Surgical treatment of deep endometriosis and risk of recurrence. Journal of Minimally Invasive Gynecology. 2005;12(6):508-13. doi: 10.1016/j.jmig.2005.06.016.
  7. Taubes G. Cancer prevention with a diabetes pill? Science. 2012;335(6064):29. doi: 10.1126/science. 335.6064.29.
  8. Bailey C, Day C. Metformin: its botanical background. Practical Diabetes International. 2004;21(3):115-7. doi: 10.1002/pdi.606.
  9. Sterne J. Du nouveau dans les antidiabetiques. La NN dimethylamine guanyl guanide (N.N.D.G.). Maroc Med. 1957;36:1295-6.
  10. Evans J. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304-5. doi: 10.1136/ bmj.38415.708634.f7.
  11. Bowker S, Majumdar S, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006;29(2):254-8. doi: 10.2337/diacare.29.02.06.dc05-1558.
  12. Menendez J, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nature Reviews Cancer. 2007;7(10):763-77. doi: 10.1038/nrc2222.
  13. Hirsch H, Iliopoulos D, Tsichlis P, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research. 2009;69(19):7507-11. doi: 10.1158/0008-5472.can-09-2994.
  14. Pulito C, Sanli T, Rana P, et al. Metformin: on ongoing journey across diabetes, cancer therapy and prevention. Metabolites. 2013;3:1051-75. doi: 10.3390/metabo3041051.
  15. Jung M, Renke T, Nowak O, et al. Modulation of the IGF system and proliferation in human endometrial stromal cells by metformin: a dose-dependent effect. Archives of Gynecology and Obstetrics. 2015;292(2):465-72. doi: 10.1007/s00404-015-3650-0.
  16. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Archives of Physiology and Biochemistry. 2008;114(1):23-37. doi: 10.1080/13813450801969715.
  17. Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576-86. doi: 10.1038/sj.onc.1211024.
  18. Tabrizi A, Melli M, Foroughi M, et al. Antiproliferative effect of metformin on the endometrium – a clinical trial. Asian Pacific Journal of Cancer Prevention. 2015;15(23):10067-70. doi: 10.7314/apjcp.2014.15.23.10067.
  19. Sharifzadeh F, Aminimoghaddam S, Kashanian M, et al. A comparison between the effects of metformin and megestrol on simple endometrial hyperplasia. Gynecological Endocrinology. 2016;33(2):152-5. doi: 10.1080/09513590.2016.1223285.
  20. Erdemoglu E, Güney M, Giray S, et al. Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2009;145(2):195-9. doi: 10.1016/j.ejogrb.2009.04.034.
  21. Tas M, Kutuk M, Serin I, et al. Comparison of antiproliferative effects of metformine and progesterone on estrogen-induced endometrial hyperplasia in rats. Gynecological Endocrinology. 2013;29(4):311-14. doi: 10.3109/09513590.2012.743010.
  22. Clement N, Oliver T, Shiwani H, et al. Metformin for endometrial hyperplasia (Protocol). Cochrane Database of Systematic Reviews. 2016(5) Art. No.: CD012214. doi: 10.1002/14651858.CD012214.
  23. Bulun S. Endometriosis. New England Journal of Medicine. 2009;360(3):268-79. doi: 10.1056/nejmra0804690.
  24. Bulun S, Cheng Y, Yin P, et al. Progesterone resistance in endometriosis: Link to failure to metabolize estradiol. Molecular and Cellular Endocrinology. 2006;248(1-2):94-103. doi: 10.1016/j.mce.2005.11.041.
  25. Huhtinen K, Desai R, Stahle M, et al. Endometrial and endometriotic concentrations of estrone and estradiol are determined by local metabolism rather than circulating levels. The Journal of Clinical Endocrinology & Metabolism. 2012;97(11):4228-35. doi: 10.1210/jc.2012-1154.
  26. Bulun S, Monsavais D, Pavone M, et al. Role of estrogen receptor-β in endometriosis. Seminars in Reproductive Medicine. 2012;30(01):39-45. doi:10.1055/ s-0031-1299596.
  27. Delvoux B, Groothuis P, D’Hooghe T, et al. Increased production of 17β-estradiol in endometriosis lesions is the result of impaired metabolism. Molecular Endocrinology. 2009;23(2):276. doi: 10.1210/mend.23.2.9993.
  28. Ярмолинская М.И. Генитальный эндометриоз: влияние гормональных, иммунологических и генетических факторов на развитие, особенности течения и выбор терапии: дис. … д-ра мед. наук. – СПб., 2009. – 408 с. [Yarmolinskaya MI. Genital’nyi endometrioz: vliyanie gormonal’nykh, immunologicheskikh i geneticheskikh faktorov na razvitie, osobennosti techeniya i vybor terapii [dissertation]. Saint Petersburg; 2009. (In Russ.)]
  29. Ferrero S, Remorgida V, Maganza C, et al. Aromatase and endometriosis: estrogens play a role. Annals of the New York Academy of Sciences. 2014;1317(1):17-23. doi: 10.1111/nyas.12411.
  30. Liu Y, Zhang W. Association between body mass index and endometriosis risk: a meta-analysis. Oncotarget. 2017. doi: 10.18632/oncotarget.14916.
  31. Bareh G, Robinson R, Schenken R. Endometriosis and Lipid Concentration. Obstetrics Gynecology. 2015;125:110S. doi: 10.1097/01.aog.0000463619. 54777.2f.
  32. Melo A, Rosa-e-Silva J, Rosa-e-Silva A, et al. Unfavorable lipid profile in women with endometriosis. Fertil Steril. 2010;93(7):2433-6. doi: 10.1016/j.fertnstert.2009.08.043.
  33. Sahmani M, Ghaleh T, Darabi M, et al. I405V polymorphism of CETP gene and lipid profile in women with endometriosis. Gynecological Endocrinology. 2013;29(7):712-5. doi: 10.3109/09513590.2013. 797396.
  34. Xu J, Zeng C, Zhou Y, et al. Metformin inhibits StAR expression in human endometriotic stromal cells via AMPK-mediated disruption of CREB-CRTC2 complex formation. The Journal of Clinical Endocrinology & Metabolism. 2014;99(8):2795-2803. doi: 10.1210/jc.2014-1593.
  35. Attar E, Tokunaga H, Imir G, et al. Prostaglandin E2 via steroidogenic factor-1 coordinately regulates transcription of steroidogenic genes necessary for estrogen synthesis in endometriosis. The Journal of Clinical Endocrinology & Metabolism. 2009;94(2):623-631. doi: 10.1210/jc.2008-1180.
  36. Bukulmez O, Hardy D, Carr B, et al. Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology. 2008;149(3):1190-1204. doi: 10.1210/en.2007-0665.
  37. Han S, Jung S, Wu S, et al. Estrogen receptor β modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis. Cell. 2015;163(4):960-74. doi: 10.1016/j.cell.2015.10.034.
  38. Simmen R, Kelley A. Reversal of fortune: estrogen receptor-β in endometriosis. Journal of Molecular Endocrinology. 2016;57(2):23-7. doi: 10.1530/jme-16-0080.
  39. Xue Q, Lin Z, Cheng Y, et al. Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis. Biology of Reproduction. 2007;77(4):681-7. doi: 10.1095/biolreprod.107.061804.
  40. Markowska A, Pawałowska M, Filas V, et al. Does Metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer? Diabetology Metabolic Syndrome. 2013;5(1):76. doi: 10.1186/1758-5996-5-76.
  41. Ярмолинская М.И., Денисова В.М. Значение генитального эндометриоза в патогенезе бесплодия // Журнал акушерства и женских болезней. — 2013. – Т. 62. – № 6. – C. 67–77. [Yarmolinskaya M, Denisova V. Importance of genital endometriosis in pathogenesis of infertility. Journal of Obstetrics and Women’s Diseases. 2013;62(6):67-77. (In Russ.)]
  42. Burney R, Talbi S, Hamilton A, et al. Gene expression analysis of endometrium reveals progesterone resistance and candidate susceptibility genes in women with endometriosis. Endocrinology. 2007;148(8):3814-26. doi: 10.1210/en.2006-1692.
  43. Shao R, Cao S, Wang X, et al. The elusive and controversial roles of estrogen and progesterone receptors in human endometriosis. Am J Transl Res. 2014;6: 104-13.
  44. Xie Y, Wang Y, Yu L, et al. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 2011;126(3-5):113-20. doi: 10.1016/j.jsbmb.2010.12.006.
  45. Aghajanova L, Hamilton A, Kwintkiewicz J, et al. Steroidogenic enzyme and key decidualization marker dysregulation in endometrial stromal cells from women with versus without endometriosis. Biology of Reproduction. 2009;80(1):105-14. doi: 10.1095/biolreprod.108.070300.
  46. Wei Q, St. Clair J, Fu T, et al. Reduced expression of biomarkers associated with the implantation window in women with endometriosis. Fertility and Sterility. 2009;91(5):1686-91. doi: 10.1016/j.fertnstert.2008.02.121.
  47. Zhuo Z, Wang A, Yu H. Metformin targeting autophagy overcomes progesterone resistance in endometrial carcinoma. Archives of Gynecology and Obstetrics. 2016;294(5):1055-61. doi: 10.1007/s00404-016-. 4148-0.
  48. Денисова В.М., Потин В.В., Ярмолинская М.И., Тимофеева Е.М. Активность овариальной ароматазы при эндометриозе // Журнал акушерства и женских болезней. – 2013. – Т. 62. – № 2. – С. 17–22. [Denisova VM, Potin VV, Jarmolinskaja MI, Timofeeva EM. Ovarian aromatase activity in endometriosis. Journal of Obstetrics and Women’s Diseases. 2013;62(2):17-22. (In Russ.)]
  49. Сельков С. А., Ярмолинская М.И., Павлов О.В., и др. Системные и локальные уровни регуляции иммунопатогенетических процессов у пациенток с наружным генитальным эндометриозом // Журнал акушерства и женских болезней. – 2005. – Т. 54. – № 1. – С. 20–28. [Sel’kov SA, Yarmolinskaya MI, Pavlov OV, et al. Sistemnye i lokal’nye urovni regulyatsii immunopatogeneticheskikh protsessov u patsientok s naruzhnym genital’nym endometriozom. Journal of Obstetrics and Women’s Diseases. 2005;54(1):20-8. (In Russ.)]
  50. Kim J, Suh C, Kim S, et al. Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP-3 protease activity in the peritoneal fluid of patients with and without endometriosis. Fertil Steril. 2000;73(5):996-1000. doi: 10.1016/s0015-0282(00)00493-3.
  51. De Leo V, la Marca A, Orvieto R, et al. Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2000;85(4):1598-1600. doi: 10.1210/jcem.85.4.6560.
  52. Kitawaki J, Kusuki I, Koshiba H, et al. Detection of aromatase cytochrome P-450 in endometrial biopsy specimens as a diagnostic test for endometriosis. Fertility and Sterility. 1999;72(6):1100-06. doi: 10.1016/s0015-0282(99)00424-0.
  53. Wolfler M. A predictive model for endometriosis. Human Reproduction. 2005;20(6):1702-08. doi: 10.1093/humrep/deh796.
  54. Velasco I. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Molecular Human Reproduction. 2006;12(6):377-81. doi: 10.1093/molehr/gal041.
  55. Молотков А.С., Ярмолинская М.И., Полякова В.О., и др. Значение экспрессии ароматазы в патогенезе наружного генитального эндометриоза // Молекулярная медицина. – 2012. – № 4. – С. 41–44. [Molotkov AS, Yarmolinskaya MI, Polyakova VO, et al. The role of aromatase expression in the pathogenesis of genital endometriosis. Molekulyarnaya meditsina. 2012;(4):41-4. (In Russ.)]
  56. Rice S, Pellatt L, Ramanathan K, et al. Metformin inhibits aromatase via an extracellular signal-regulated kinase-mediated pathway. Endocrinology. 2009;150(10):4794-801. doi: 10.1210/en.2009-0540.
  57. Chen G, Nunez G. Sterile inflammation: sensing and reacting to damage. Nature Reviews Immunology. 2010;10(12):826-37. doi: 10.1038/nri2873.
  58. Ярмолинская М.И. Цитокиновый профиль перитонеальной жидкости и периферической крови больных с наружным генитальным эндометриозом // Журнал акушерства и женских болезней. – 2008. – Т. 57. – № 3. – C. 30–34. [Yarmolinskaya MI. Cytokine profile of peritoneal fluid and paerpheral blood in patients with pelvic endometriosis. Journal of Obstetrics and Women’s Diseases. 2008;57(3):30-4 (In Russ.)]
  59. Beste M, Pfaffle-Doyle N, Prentice E, et al. Endometriosis: Molecular network analysis of endometriosis reveals a role for c-Jun-regulated macrophage activation. Science Translational Medicine. 2014;6(222):Article ID222ra16. doi: 10.1126/scitranslmed.3007988.
  60. Koch A, Polverini P, Kunkel S, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258(5089):1798-1801. doi: 10.1126/science.1281554.
  61. McLaren J, Prentice A, Charnock-Jones D, et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. Journal of Clinical Investigation. 1996;98(2):482-9. doi: 10.1172/jci118815.
  62. Bacci M, Capobianco A, Monno A, et al. Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease. The American Journal of Pathology. 2009;175(2):547-56. doi: 10.2353/ajpath.2009.081011.
  63. Kwak J, Park S, Kim K, et al. Modulation of neutrophil apoptosis by plasma and peritoneal fluid from patients with advanced endometriosis. Human Reproduction. 2002;17(3):595-600. doi: 10.1093/humrep/17.3.595.
  64. Gazvani R, Smith L, Fowler P. Effect of interleukin-8 (IL-8), anti-IL-8, and IL-12 on endometrial cell survival in combined endometrial gland and stromal cell cultures derived from women with and without endometriosis. Fertility and Sterility. 2002;77(1):62-7. doi: 10.1016/s0015-0282(01)02954-5.
  65. Zarrouk M, Finlay D, Foretz M, et al. Adenosine-mono-phosphate-activated protein kinase-independent effects of metformin in T-cells. PLoS ONE. 2014;9(9): e106710. doi: 10.1371/journal.pone.0106710.
  66. Zhang D, Meng F, Zhou J, et al. Effect of Metformin on Proliferation, Differentiation and Apoptosis of THP-1 Cells. Journal of experimental hematology/Chinese Association of Pathophysiology. 2015;23(3):633-6. doi: 10.7534/j.issn.1009-2137.2015.03.006.
  67. Oner G, Ozcelik B, Ozgun M, et al. The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model. Human Reproduction. 2010;25(4):932-7. doi: 10.1093/humrep/deq016.
  68. Yilmaz B, Sucak A, Kilic S, et al. Metformin regresses endometriotic implants in rats by improving implant levels of superoxide dismutase, vascular endothelial growth factor, tissue inhibitor of metalloproteinase-2, and matrix metalloproteinase-9. American Journal of Obstetrics and Gynecology. 2010;202(4):368.e1-368.e8. doi: 10.1016/j.ajog.2009.10.873.
  69. Foda A. Metformin as a new therapy for endometriosis, its effects on both clinical picture and cytokines profile. Middle East Fertility Society Journal. 2012;17(4):262-7. doi: 10.1016/j.mefs.2012.09.001.
  70. Omer N, Taher M, Skheel H. Effect of metformin treatment on some blood biomarkers in women with endometriosis. Iraqi Journal of Pharmaceutical Sciences. 2017;25(1):28-36.


Abstract - 1047

PDF (Russian) - 419


CrossRef     1 citations

  • Asghari S, Valizadeh A, Aghebati-Maleki L, Nouri M, Yousefi M. Endometriosis: Perspective, lights, and shadows of etiology. Biomedicine & Pharmacotherapy. 2018;106:163. doi: 10.1016/j.biopha.2018.06.109


Copyright (c) 2017 Florova M.S., Yarmolinskaya M.I., Potin V.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.